Source-grounded facts extracted from ROCKWELL MEDICAL, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ROCKWELL MEDICAL, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“May 8, 2026, Rockwell Medical, Inc. (the “Company”) received written notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price require”
ROCKWELL MEDICAL, INC. reported fiscal year 2026 results: revenue $70.0M to $75.0M.
“Rockwell Medical updates its 2026 annual guidance as follows: 2026 Annual Guidance Net Sales $70.0M to $75.0M Gross Margin 18% to 22% Adjusted EBITDA $1.0M to $2.0M Operating Cash Flow Positive”
ROCKWELL MEDICAL, INC. reported the three months ended March 31, 2026 results: revenue $17.3 million, net income $1.6 million, EPS $(0.04).
“reference in such a filing. --- EX-99.1 (EX-99.1) --- Rockwell Medical Announces First Quarter 2026 Results and Additional 2026 Guidance with Focus on Profitability • Reports $17.3 million in net sales, $2.9 million in gross profit, and 17% gross margin in the first quarter 2026. • Announces operational changes that are expected to generate more than $3 million in”
ROCKWELL MEDICAL, INC. reported the twelve months ended December 31, 2025 results: revenue $69.3 million, net income $ (5.3) million, EPS $ (0.15) per share.
“--- Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results • Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively. • Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025. • Generated 21% in gross margin for the fourth quarter 2025,”
ROCKWELL MEDICAL, INC. reported the three months ended December 31, 2025 results: revenue $18.3 million, net income $ (0.6) million, EPS $ (0.01) per share.
“EX-99.1 (EX-99.1) --- Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results • Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively. • Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025. • Generated 21% in gross margin for the fourth”
ROCKWELL MEDICAL, INC. reported three months ended March 31, 2024 results: revenue $22.7 million, net income Net loss of $1.7 million, EPS $(0.06). Guidance raised.
“by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Rockwell Medical Announces First Quarter 2024 Results, Raises 2024 Guidance • Reports record net sales of $22.7 million for the first quarter of 2024, an increase of 25% over net product sales and a 15% increase over net sales for the same period in 2023. • Reports record gross profit of $3.1”
ROCKWELL MEDICAL, INC. updated its the three months and twelve months ended December 31, 2023 guidance (initiated).
“Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide , today announced financial and operational results for the three months and twelve months ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.